Clinical Trial Detail

NCT ID NCT02132949
Title A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer.
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Hoffmann-La Roche
Indications

Her2-receptor positive breast cancer

Therapies

Pertuzumab + Trastuzumab

Cyclophosphamide + Doxorubicin + Paclitaxel

Cyclophosphamide + Docetaxel + Epirubicin + Fluorouracil

Age Groups: adult

Additional content available in CKB BOOST